Provider Perspectives on Beta-lactam Therapeutic Drug Monitoring Programs in the Critically Ill

Completed

• Conditions: Critical Illness; Sepsis

• Registration Number: NCT04755777
• Lead Sponsor: Mayo Clinic

Brief Summary

The purpose of the study is to characterize various healthcare practitioners' perspectives on implementation of beta-lactam therapeutic drug monitoring in critical care practice.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-10-22
• Study First Submitted: 2021-02-10
• Study First Submitted QC: 2021-02-12
• Study First Posted: 2021-02-16
• Primary Completion: 2022-12-31
• Study Completion: 2022-12-31
• Status Verified: 2023-02
• Last Update Submitted: 2023-02-18
• Last Update Posted: 2023-02-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 138

Inclusion Criteria

• Providers involved with beta-lactam TDM for critically ill patients

Read More

Exclusion Criteria

• None

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Frequency of drug level testing recommended	Baseline	Indication of how many critically ill patients treated with beta-lactams should receive TDM.
Nature of drug level testing recommended	Baseline	Indication of which types of critically ill patients treated with beta-lactams should receive TDM

Secondary Outcome Measures

Name	Time	Method
Determinants of beta-lactam TDM implementation	Baseline	List of factors associated with successful beta-lactam TDM implementation

Trial Locations

Locations (3)

UF Health Shands; 🇺🇸 Gainesville, Florida, United States

Mayo Clinic; 🇺🇸 Rochester, Minnesota, United States

Royal Brisbane and Women's Hospital; 🇦🇺 Herston, Queensland, Australia